Albireo, a company focused through its operating subsidiary on the development of bile acid modulators to treat orphan pediatric and adult liver diseases, NASH, and gastrointestinal disorders, has announced that Ron Cooper has joined the company as President and Chief Executive Officer. In addition, Albireo has established a US subsidiary office in Boston, Massachusetts.

Mr. Cooper is a global biopharmaceutical leader with a track record of growing businesses, brands and organizations in the U.S. and Europe. He joins Albireo from Bristol-Myers Squibb (BMS), where he was President of Europe.

“We are pleased to welcome Ron as the new CEO of Albireo,” said Dr. David Chiswell, Chairman of Albireo’s board of directors. “Ron’s management skills and impressive track record with blockbuster drugs make him uniquely qualified to drive Albireo’s strategic direction as we advance our promising pipeline of mid- and late-stage product candidates in disease areas with significant unmet medical need.”

“I am delighted to join Albireo at such an exciting time for the company,” said Mr. Cooper. “We expect to achieve several value-generating milestones in the coming months, including data readouts for our three lead assets. I look forward to helping Albireo’s team of world-class experts in bile acid biology deliver on the promise of our pipeline.”

During his more than 25 years at BMS, Mr. Cooper worked in five different countries and held positions of increasing responsibility in sales, marketing and general management, culminating as President of Europe. He was responsible for more than 30 countries with sales exceeding $4.5 billion. He has successfully completed more than a dozen business development transactions, including the creation of the first single tablet HIV/AIDS regimen partnership. Mr. Cooper is a graduate of St. Francis Xavier University in Canada.

Source: Albireo